Grundlæggende statistik
| CIK | 1711786 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Rocket One Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2026 Rocket One Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 3, 2026 |
Up to $6,829,000 Common Stock Rocket One Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-291566 AMENDMENT NO. 2 DATED JUNE 3, 2026 TO PROSPECTUS SUPPLEMENTS DATED APRIL 16, 2026 AND MAY 27, 2026 (To Prospectus Dated December 4, 2025) Up to $6,829,000 Common Stock Rocket One Inc. This Amendment No. 2 to prospectus supplement (“Amendment No. 2”) amends and supplements the information in the prospectus, dated December 4, 2025, filed a |
|
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 3, 2026 Rocket One Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 3, 2026 |
Exhibit 99.1 Adelina: 4702663 ROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.) TO SPACE AND DEFENSE ADVISORY BOARD Former U.S. Army Major General Brings Decades of National Security, Strategic Operations, and Defense Leadership Experience to Support Rocket One's Expansion into AI Infrastructure for Space, and Defense Applications HOBOKEN, NJ — June 3, 2026 — (Nasdaq: RKTO) Rocket One, Inc |
|
| June 2, 2026 |
Exhibit 99.1 Conf# 4700878 Rocket One Appoints Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology Pioneering nanomagnetics researcher to guide development of the company’s radiation-tolerant, ultra-low-power AI chip platform NEW YORK — June 1, 2026 — Rocket One Inc. (Nasdaq: RKTO) today announced the appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor |
|
| June 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 1, 2026 Rocket One Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 28, 2026 |
Exhibit 99.1 Rocket One Accepted into AMD AI Developer Program to Advance Simulation of Next-Generation Nanomagnetic AI Accelerator Architecture for AI, Defense and Space Applications Access to AI Developer Cloud Resources is Expected to be Utilized to Support Modeling of Energy-Efficient Semiconductor Technologies for AI, Defense and Space Applications HOBOKEN, NJ — May 28, 2026 — Rocket One Inc. |
|
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 27, 2026 Rocket One Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 27, 2026 |
Up to $2,661,176 Common Stock Rocket One Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-291566 AMENDMENT NO. 1 DATED MAY 27, 2026 TO PROSPECTUS SUPPLEMENT DATED APRIL 16, 2026 TO PROSPECTUS DATED DECEMBER 4, 2025 Up to $2,661,176 Common Stock Rocket One Inc. This Amendment No. 1 to prospectus supplement (“Amendment”) amends and supplements the information in the prospectus, dated December 4, 2025, filed as a part of our registrati |
|
| May 27, 2026 |
Exhibit 3.1 Business Number E0234272017 - 6 Filed in the Office of Filing Number 20265755587 Secretary of State State Of Nevada Filed On 5/20/2026 2:43:00 PM Number of Pages 2 FRANCISCO V. AGUILAR Secretary of State 401 North Carson Street Carson City, Nevada B97d1 - 42D1 (775) 684 - 5708 Website: www.nvsos.gov Profit Corporation: Certificate of Amendment (PURSUANT TO NRS 78 380 & 78 385 78.390) |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2026 Hoth Therapeutics, Inc. (Now Known As Rocket One Inc.) (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of i |
|
| May 27, 2026 |
Exhibit 99.1 Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense Applications Company Adopts Space-Focused Identity, New Ticker “RKTO,” and Exclusive License of AI Chip Architecture Designed for Ultra-Low-Power, Radiation-Tolerant Computing |
|
| May 21, 2026 |
Exhibit 10.2 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (the “Agreement”) is made and entered into this 15th day of May, 2026 (the “Effective Date”), by and between Rocket One Inc and its Affili |
|
| May 21, 2026 |
Exhibit 99.1 AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture Company Targets Power Demands of AI Data Centers Through Patented Nanomagnetic Semiconductor and Sp |
|
| May 21, 2026 |
Exhibit 10.1 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (the “Agreement”) is made and entered into this 15th day of May, 2026 (the “Effective Date”), by and between Rocket One Inc and its Affili |
|
| May 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2026 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| May 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2026 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 4, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 30, 2026 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 16, 2026 |
Up to $1,555,000 Common Stock Hoth Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-291566 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 4, 2025) Up to $1,555,000 Common Stock Hoth Therapeutics, Inc. We have entered into an At The Market Offering Agreement dated as of November 8, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), relating to the sale of our common stock, par |
|
| April 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2026 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 2, 2026 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2026, between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| April 2, 2026 |
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT HOTH THERAPEUTICS, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 2, 2026 |
Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering Exhibit 99.2 Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering NEW YORK, April 2, 2026 – Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,8 |
|
| April 2, 2026 |
2,857,144 Shares of Common Stock Filed pursuant to Rule 424(B)(5) Registration No. 333-291566 PROSPECTUS SUPPLEMENT (To Prospectus Dated December 4, 2025) 2,857,144 Shares of Common Stock We are offering 2,857,144 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus supplement and the accompanying prospectus to several institutional investors. The purchase price of each share of common stock to the |
|
| April 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 1, 2026 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| April 2, 2026 |
Hoth Therapeutics Announces $2.0 Million Registered Direct Offering Exhibit 99.1 Hoth Therapeutics Announces $2.0 Million Registered Direct Offering NEW YORK, April 1, 2026 – Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,857,144 shares of its common st |
|
| April 2, 2026 |
COMMON STOCK PURCHASE WARRANT HOTH THERAPEUTICS, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 27, 2026 |
HOTH THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS Exhibit 14.1 HOTH THERAPEUTICS, INC. CODE OF BUSINESS CONDUCT AND ETHICS Hoth Therapeutics, Inc. (the “Company”) has adopted the following Code of Business Conduct and Ethics (this “Code”) for directors, executive officers and employees of the Company. This Code is intended to focus the directors, executive officers and employees on areas of ethical risk, provide guidance to directors, executive o |
|
| March 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (E |
|
| March 27, 2026 |
Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2025, Hoth Therapeutics, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description |
|
| January 16, 2026 |
Exhibit 99.1 January 2026 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believe |
|
| January 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 16, 2026 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| December 2, 2025 |
Hoth Therapeutics, Inc. 1177 Avenue of the Americas, 5th Floor, Suite 5066 New York, New York 10036 Hoth Therapeutics, Inc. 1177 Avenue of the Americas, 5th Floor, Suite 5066 New York, New York 10036 December 2, 2025 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Gama Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-291566 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulatio |
|
| November 17, 2025 |
HOTH THERAPEUTICS INC., DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Exhibit 4.3 HOTH THERAPEUTICS INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 Se |
|
| November 17, 2025 |
HOTH THERAPEUTICS INC., DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Exhibit 4.4 HOTH THERAPEUTICS INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificat |
|
| November 17, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-3 Hoth Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, |
|
| November 17, 2025 |
As filed with the Securities and Exchange Commission on November 14, 2025 As filed with the Securities and Exchange Commission on November 14, 2025 Registration No. |
|
| November 13, 2025 |
Up to $4,821,200 Common Stock Hoth Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-272620 AMENDMENT NO. 2 DATED NOVEMBER 13, 2025 TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 8, 2024 TO PROSPECTUS DATED JUNE 16, 2023 Up to $4,821,200 Common Stock Hoth Therapeutics, Inc. This Amendment No. 2 to prospectus supplement (“Amendment”) amends and supplements the information in the prospectus, dated June 16, 2023, filed as a part of our r |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Ther |
|
| October 17, 2025 |
Exhibit 99.1 October 2025 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believe |
|
| October 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 17, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| September 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 12, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| August 22, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated August 22, 2025 (the “Effective Date”), is by and between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and Robb Knie (the “Executive”). WHEREAS, the Company and Executive entered into that certain Employment Agreement, dated March 28, 2023 (the “Prior Employment Agreement”); WHEREAS, the Company |
|
| August 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 20, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeut |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 5, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Hoth Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Common Stock, |
|
| August 5, 2025 |
Amendment No. 2 to Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan Exhibit 10.3 AMENDMENT NO. 2 TO HOTH THERAPEUTICS, INC. AMENDED AND RESTATED 2022 OMNIBUS EQUITY INCENTIVE PLAN Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), hereby amends its Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Plan”) as set forth below, which amendments shall be effective as the date set forth below, but if and only if the Company’s shareholders approve |
|
| August 5, 2025 |
As filed with the Securities and Exchange Commission on August 5, 2025 As filed with the Securities and Exchange Commission on August 5, 2025 Registration No. |
|
| June 24, 2025 |
Exhibit 99.1 HT - 001 The first therapy for EGFR inhibitor induced cutaneous toxicities Innovating for Everyone Safe Harbor Statement A significant unmet need Cancer patients on EGFR inhibitors experiencing severe dermatological side effects are limited to dose - reduction or stopping treatment entirely Epidermal growth factor receptor inhibitors (EGFRIs) are used in multiple cancer types affectin |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 20, 2025 |
Exhibit 99.1 Hoth Therapeutics Regains Nasdaq Compliance – Clears Key Listing Hurdle, Reaffirms Path Toward Growth June 18 2025 – NEW YORK, NY – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full compliance with Nasdaq’s minimum bid price requirement. On June 18, 2025, the Company received |
|
| June 20, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 9, 2025 |
Exhibit 99.1 June 2025 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believe,” |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| May 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 2, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File N |
|
| April 15, 2025 |
Exhibit 99.1 Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 in Open-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): ● Patients experienced a 50% reduction in pruritus severity, with mean scores droppin |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 9, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| March 28, 2025 |
Exhibit 10.36 HOTH THERAPEUTICS, INC. RESTRICTED STOCK UNIT AWARD GRANT NOTICE (2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Hoth Therapeutics, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, you have been granted a Rest |
|
| March 28, 2025 |
Amended and Restated Insider Trading Policy Exhibit 19.1 AMENDED & RESTATED Insider Trading POLICY (Effective Date: February 5, 2025) INTRODUCTION & REASONS FOR AN INSIDER TRADING POLICY The Board of Directors (the “Board”) of Hoth Therapeutics Inc. (the “Company”) has adopted this amended & restated insider trading policy (this “Policy”) to promote compliance by Insiders (as defined below) with laws that prohibit certain persons aware of m |
|
| March 28, 2025 |
Exhibit 10.32 GRANT NO. HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby grants an Option to purchase Shares to the Optionee named below. The terms and conditions of the Option are set forth in this cover sheet, in the attached Incentive Stock Option Agreement and in the Company’s 2018 Equity Incentive Plan (the “Pla |
|
| March 28, 2025 |
Exhibit 10.33 GRANT NO. HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN NONSTATUTORY STOCK OPTION AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby grants an Option to purchase Shares to the Optionee named below. The terms and conditions of the Option are set forth in this cover sheet, in the attached Nonstatutory Stock Option Agreement and in the Company’s 2018 Equity Incentive Plan (th |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 28, 2025 |
Form of Stock Unit Agreement pursuant to the Hoth Therapeutics, Inc. 2018 Equity Incentive Plan Exhibit 10.34 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN STOCK UNIT AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby awards Stock Units to the Participant named below. The terms and conditions of the Award are set forth in this cover sheet, in the attached Stock Unit Agreement and in the Company’s 2018 Equity Incentive Plan (the “Plan”). This cover sheet is incorporated into and a |
|
| March 28, 2025 |
Description of the Registrant’s Securities EXhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2024, Hoth Therapeutics, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description |
|
| March 28, 2025 |
Exhibit 10.35 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT AGREEMENT Hoth Therapeutics, Inc. (the “Company”) hereby awards a Restricted Stock Grant (the “Restricted Stock”) to the Participant named below. The terms and conditions of the Restricted Stock Grant are set forth in this cover sheet and the attached Restricted Stock Grant Agreement and in the Company’s 2018 E |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 25, 2025 |
Agreement by and between the Company and OnTargetx R&D Inc. dated March 24, 2025 Exhibit 10.1 CONFIDENTIAL Project Order / Proposal N-0006 24-MAR-2025 OnTargetx R&D Inc. THIS PROJECT ORDER NO. N-0006 is between Hoth Therapeutics (“CLIENT”) and OnTargetx R&D Inc. (“PROVIDER”), which upon execution by both parties, shall be incorporated into and subject to the terms and conditions of the Master Service Agreement between Hoth Therapeutics and PROVIDER. CLIENT hereby engages PROVI |
|
| February 7, 2025 |
Up to $5,000,000 Common Stock Common Stock Hoth Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-272620 PROSPECTUS SUPPLEMENT (To Prospectus dated June 16, 2023 To Prospectus Supplement dated November 8, 2024) Up to $5,000,000 Common Stock Common Stock Hoth Therapeutics, Inc. This prospectus supplement (“Prospectus Supplement”) amends and supplements the information in the prospectus, dated June 16, 2023, filed as a part of our registratio |
|
| February 7, 2025 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 24, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 23, 2025 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 24, 2025 |
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements New York, NY – January 24, 2025 – Hoth Therapeutics, Inc. (NASDAQ: HOTH) (the “Company” or “Hoth Therapeutics”), a biopharmaceutical company, today announced that it has received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance |
|
| December 2, 2024 |
Exhibit 99.1 December 2024 Innovating for Everyone Clinical - stage biopharmaceutical company focused on next generation therapeutics meeting unmet patient needs. This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words “could,” “believ |
|
| December 2, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 2, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 20, 2024 |
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset Exhibit 99.1 Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset NEW YORK, November 20, 2024 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company’s Board of Directors approved the purchase of up to $1 million in Bitcoin. “As Bitcoin continues to grow, gaining investor attention and acceptance as a major |
|
| November 20, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 20, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
Up to $2,700,000 Common Stock Hoth Therapeutics, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-272620 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 16, 2023) Up to $2,700,000 Common Stock Hoth Therapeutics, Inc. We have entered into an At The Market Offering Agreement dated as of November 8, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent” or “Wainwright”), relating to the sale of our common stock, par va |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Ther |
|
| November 8, 2024 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 8, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 8, 2024 |
Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT November 8, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Hoth Therapeutics, Inc., a corporation organized under the laws of Nevada (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in thi |
|
| November 1, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| August 16, 2024 |
As filed with the Securities and Exchange Commission on August 16, 2024 As filed with the Securities and Exchange Commission on August 16, 2024 Registration No. |
|
| August 16, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hoth Therapeutics, Inc. |
|
| August 16, 2024 |
Exhibit 10.2 Appendix A AMENDMENT NO. 1 TO HOTH THERAPEUTICS, INC. AMENDED AND RESTATED 2022 OMNIBUS EQUITY INCENTIVE PLAN Hoth Therapeutics, Inc., a Nevada corporation (the “Company”) hereby amends its Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Plan”) as set forth below, which amendments shall be effective as the date set forth below, but if and only if the Company’s shareholde |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeut |
|
| August 7, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 14, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 17, 2024 |
Amendment No. 2 to the Amended and Restated Bylaws of Hoth Therapeutics, Inc. Exhibit 3.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED BYLAWS OF HOTH THERAPEUTICS, INC. a Nevada Corporation Pursuant to resolutions of the Board of Directors (the “Board”) of Hoth Therapeutics, Inc. a Nevada corporation (the “Corporation”) adopted via unanimous written consent of the Board on June 14, 2024 and in accordance with the authority provided to the directors pursuant to Article X, Section |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| April 22, 2024 |
Hoth Therapeutics, Inc. Up to 5,030,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278620 PROSPECTUS Hoth Therapeutics, Inc. Up to 5,030,000 Shares of Common Stock Pursuant to this prospectus, the selling stockholders identified herein (the “Selling Stockholders”) are offering on a resale basis an aggregate of 5,030,000 shares of common stock, par value $0.001 per share (the “Common Stock”) of Hoth Therapeutics, Inc. (the “Co |
|
| April 18, 2024 |
Hoth Therapeutics, Inc. 590 Madison Ave., 21st Floor New York, NY 10022 Hoth Therapeutics, Inc. 590 Madison Ave., 21st Floor New York, NY 10022 April 18, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Re: Hoth Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278620 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act |
|
| April 17, 2024 |
United States securities and exchange commission logo April 17, 2024 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. |
|
| April 11, 2024 |
As filed with the Securities and Exchange Commission April 11, 2024 As filed with the Securities and Exchange Commission April 11, 2024 Registration Statement No. |
|
| April 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) HOTH THERAPEUTICS, INC. |
|
| March 28, 2024 |
Exhibit 97.1 HOTH THERAPEUTICS, INC. CLAWBACK POLICY I. Purpose and Scope The Board of Directors (the “Board”) of the Company believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted this Cl |
|
| March 28, 2024 |
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds Exhibit 99.1 Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds NEW YORK, March 27, 2024 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of common stock of |
|
| March 28, 2024 |
Form of Warrant Inducement Agreement Exhibit 10.36 Hoth Therapeutics, Inc. March 27, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Hoth Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per share |
|
| March 28, 2024 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia merveille.ai Nevada |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 28, 2024 |
Exhibit 10.1 Hoth Therapeutics, Inc. March 27, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Hoth Therapeutics, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s common stock, par value $0.0001 per share |
|
| March 28, 2024 |
4,600,000 Shares of Common Stock Filed pursuant to rule 424(b)(3) Registration Statement No. 333-269224 Prospectus Supplement (To the Prospectus dated January 25, 2023) 4,600,000 Shares of Common Stock This prospectus supplement updates, supersedes and amends certain information contained in the prospectus dated January 25, 2023 (the “Original Prospectus”), relating to the offering on a resale basis of an aggregate of 4,600,000 S |
|
| March 28, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 28, 2024 |
Exhibit 4.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 27, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 14, 2024 |
HOTH / Hoth Therapeutics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 8, 2024 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth T |
|
| October 5, 2023 |
Articles of Incorporation of merveille.ai Exhibit 3.1 |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 4, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| September 15, 2023 |
Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT HOTH THERAPEUTICS, INC. Warrant Shares: Issue Date:, 2023 Initial Exercise Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| September 15, 2023 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 15, 2023 |
Exhibit 99.2 Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules NEW YORK, Sept. 15, 2023 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH) (“Hoth” or the “Company”), a patient-focused biopharmaceutical company, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq |
|
| September 15, 2023 |
Form of Placement Agent Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 15, 2023 |
Exhibit 99.1 Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules NEW YORK, Sept. 13, 2023 /PRNewswire/ - Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the purchase and sale of 1,100,000 shares of its common stock (or common stock equiva |
|
| September 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 13, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| September 15, 2023 |
Form of Securities Purchase Agreement Exhibit 10.1 $2.SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 13, 2023, between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and condi |
|
| September 14, 2023 |
Filed pursuant to Rule 424(B)(5) Registration No. 333-272620 PROSPECTUS SUPPLEMENT (To Prospectus Dated June 16, 2023) 549,275 Shares of Common Stock Pre-Funded Warrants to Purchase 550,725 Shares of Common Stock (and the shares of Common Stock underlying the Pre-Funded Warrants) We are offering 549,275 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus supplement |
|
| August 21, 2023 |
Exhibit 10.1 HOTH THERAPEUTICS, INC. AMENDED AND RESTATED 2022 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the Hoth Therapeutics, Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affil |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 18, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 21, 2023 |
Exhibit 10.2 HOTH THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Hoth Therapeutics, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, yo |
|
| August 21, 2023 |
Exhibit 10.3 HOTH THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT (Amended and Restated 2022 Omnibus Equity Incentive Plan) As a key leader in our business, you are in a position to have significant influence on the performance and success of Hoth Therapeutics, Inc. (the “Company”). I am pleased to inform you that, in recognition of the role you play in our collective success, yo |
|
| August 21, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) HOTH THERAPEUTICS, INC. |
|
| August 21, 2023 |
As filed with the Securities and Exchange Commission on August 21, 2023 As filed with the Securities and Exchange Commission on August 21, 2023 Registration No. |
|
| August 17, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 17, 2023 |
Exhibit 99.1 |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therap |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 15, 2023 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 June 15, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-272620 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Secur |
|
| June 15, 2023 |
United States securities and exchange commission logo June 15, 2023 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. |
|
| June 13, 2023 |
EX-FILING FEES 6 ea180051ex-feehoththerape.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) HOTH THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share(1) Maximum Aggregate Offering Pric |
|
| June 13, 2023 |
Exhibit 4.3 HOTH THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certificate 5 S |
|
| June 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 13, 2023 As filed with the U.S. Securities and Exchange Commission on June 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or org |
|
| June 13, 2023 |
Form of Subordinated Indenture Exhibit 4.4 HOTH THERAPEUTICS, INC., ISSUER AND [TRUSTEE], TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 Section 1.1 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.1 Designation and Terms of Securities 4 Section 2.2 Form of Securities and Trustee’s Certifica |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: Commission File Number: 001-38803 Hoth Therapeu |
|
| March 31, 2023 |
Exhibit 10.36 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated March 28, 2023 (the “Effective Date”), is by and among Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and Robb Knie (the “Executive”). WHEREAS, the Company and Executive entered into that certain Amended and Restated Employment Agreement, dated February 20, 2019, and as amended on July 1, 2021 (t |
|
| March 31, 2023 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia |
|
| March 31, 2023 |
Exhibit 10.5 These General Terms and Conditions apply to Office/Co-Working, Virtual Office and Membership agreements for services We supply to You. 1. General Agreement 1.1. Nature of an agreement: At all times, each Center remains in Our possession and control. YOU ACCEPT THAT AN AGREEMENT CREATES NO TENANCY INTEREST, LEASEHOLD ESTATE, OR OTHER REAL PROPERTY INTEREST IN YOUR FAVOR WITH RESPECT TO |
|
| March 31, 2023 |
Description of the Registrant’s Securities Exhibit 4.5 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, Hoth Therapeutics, Inc. (“the Company”) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), its common stock, par value $0.0001 per share (the “Common Stock”). Description |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 24, 2023 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
US44148G2049 / Hoth Therapeutics / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G204 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 26, 2023 |
4,600,000 Shares of Common Stock 424B3 1 ea172076-424b3hoththerap.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-269224 PROSPECTUS 4,600,000 Shares of Common Stock The selling shareholders named in this prospectus may use this prospectus to offer and resell from time to time up to 4,600,000 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 140,000 shares (the “Shares”) of ou |
|
| January 23, 2023 |
United States securities and exchange commission logo January 23, 2023 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. |
|
| January 23, 2023 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 CORRESP 1 filename1.htm Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 January 23, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Arzhang Navai Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed January 13, 2023 File No. 333-269224 Ladies and Gentlemen: Pursuant to Rule 461 of |
|
| January 13, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Hoth Therapeutics, Inc. |
|
| January 13, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 13, 2023 As filed with the U.S. Securities and Exchange Commission on January 13, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or |
|
| January 4, 2023 |
United States securities and exchange commission logo January 4, 2023 David Briones Chief Financial Officer Hoth Therapeutics, Inc. |
|
| January 3, 2023 |
HOTH THERAPEUTICS, INC. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 HOTH THERAPEUTICS, INC. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 January 3, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F. Street, NE Washington, DC 20549 Attention: Vanessa Robertson Kevin W. Vaughn Re: Hoth Therapeutics, Inc. Form 10-K for the Fiscal Year Ended December 31, 2021 Filed March 30, 2022 File No. 001-38803 Dear Ladies and Gentlemen: This letter |
|
| December 30, 2022 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 30, 2022 |
Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, December 29, 2022/ PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,000,000 shares of its common stock (or common stock |
|
| December 30, 2022 |
Form of Registration Rights Agreement Exhibit 10.4 [*] CERTAIN INFORMATION IN THIS DOCUMENT HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL AND THE OMITTED INFORMATION IS NOT MATERIAL. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 29, 2022, between Hoth Therapeutics, Inc., |
|
| December 30, 2022 |
Form of Placement Agent Warrants Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 30, 2022 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 29, 2022, between Hoth Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| December 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 29, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| December 30, 2022 |
Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| December 13, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This TRANSITION Agreement and General Release (the “AGREEMENT”) is made and entered by and between Hoth Therapeutics, Inc., including its parents, subsidiaries, and affiliates, (collectively, the “COMPANY”), on the one hand, and Stefanie Johns (“EMPLOYEE”), on the other hand (EMPLOYEE and the COMPANY are collectively referred to herein as the “ |
|
| December 13, 2022 |
Exhibit 3.1 |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 7, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| December 7, 2022 |
United States securities and exchange commission logo December 7, 2022 David Briones Chief Financial Officer Hoth Therapeutics, Inc. |
|
| November 14, 2022 |
DEF 14A 1 ea168522-def14ahoththerape.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for U |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| November 10, 2022 |
Exhibit 10.1 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This Third Amendment (this ?Amendment?) to the Employment Agreement is dated as of November 10, 2022, and effective this same date, and is entered into by and between Hoth Therapeutics, Inc., a Nevada corporation (the ?Corporation?), and Stefanie Johns (the ?Employee?). All capitalized terms used herein but not otherwise defined shall have the m |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 10, 2022 |
Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements EX-99.1 2 ea168347ex99-1hoththera.htm PRESS RELEASE DATED NOVEMBER 9, 2022 Exhibit 99.1 Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements NEW YORK, November 9, 2022 2022 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on November 9, 2022, i |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| November 3, 2022 |
Exhibit 3.1 HOTH THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF SERIES B PREFERRED STOCK The following recital and resolution was duly adopted by the board of directors (the “Board of Directors”) of Hoth Therapeutics, Inc., a Nevada corporation (the “Corporation”), in accordance with the provisions of Nevada Revised Statutes (“NRS”) 78.1955: WHEREAS, the articles of incorporation of the Corporat |
|
| November 3, 2022 |
Subscription and Investment Representation Agreement dated November 2, 2022 Exhibit 10.1 It is the responsibility of any investor purchasing these securities to satisfy itself as to full observance of the laws of any relevant territory outside the United States in connection with any such purchase, including obtaining any required governmental or other consents or observing any other applicable requirements. We are not making an offer to sell these securities in any juris |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 20, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| October 24, 2022 |
Exhibit 3.1 |
|
| October 24, 2022 |
Exhibit 99.1 Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 NEW YORK, NY October 24, 2022 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 19, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 22, 2022 |
Exhibit 3.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED BYLAWS OF HOTH THERAPEUTICS, INC. a Nevada Corporation Pursuant to resolutions of the Board of Directors (the ?Board?) of Hoth Therapeutics, Inc. a Nevada corporation (the ?Corporation?) adopted at a meeting of the Board held on August 19, 2022 and in accordance with the authority provided to the directors pursuant to Article X, Section 10.1 of t |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| July 18, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 18, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| July 18, 2022 |
Exhibit 99.1 |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 As filed with the Securities and Exchange Commission on July 1, 2022 ?Registration No. |
|
| July 1, 2022 |
EX-FILING FEES 4 ea162151ex-feehoththerape.htm FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) HOTH THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit M |
|
| July 1, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 29, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 23, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 13, 2022 |
Exhibit 99.1 |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| April 29, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 29, 2022 |
Exhibit 99.1 Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs APRIL 2022 Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ?could,? ?believe,? ?a |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 13, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 11, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 13, 2022 |
Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock NEW YORK, April 11, 2022 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton, division of Benchmark Investments, LLC, is acting as the sole book-running manager for the offering. The propose |
|
| April 13, 2022 |
424B5 1 ea158364-424b5hoththerape.htm PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(B)(5) Registration No. 333-236887 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 11, 2020) 8,235,294 Shares Common Stock We are offering 8,235,294 shares of our common stock, $0.0001 par value per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on The N |
|
| April 13, 2022 |
Exhibit 99.2 Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market NEW YORK, NY April 11, 2022/ PR Newswire / Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,294 shares of common stock (the ?Common Stock?) at a public offering price of |
|
| April 13, 2022 |
Exhibit 1.1 8,235,294 SHARES of Common Stock Hoth Therapeutics, Inc. UNDERWRITING AGREEMENT April 11, 2022 EF Hutton, division of Benchmark Investments, LLC As Representative of the Several Underwriters named on Schedule I attached hereto 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: The undersigned, Hoth Therapeutics, Inc., a company incorporated under the laws of |
|
| April 11, 2022 |
SUBJECT TO COMPLETION DATED APRIL 11, 2022 Filed pursuant to Rule 424(B)(5) Registration No. 333-236887 This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securit |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 4, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| April 4, 2022 |
PRE 14A 1 ea157893-pre14ahoththerape.htm PRELIMINARY PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38803 HOTH THERAPEUTICS, INC. (Exac |
|
| March 30, 2022 |
Subsidiaries of the registrant Exhibit 21.1 List of Subsidiaries of Hoth Therapeutics, Inc. Name State/Country of Organization or Incorporation Hoth Therapeutics Australia Pty Ltd Australia |
|
| March 30, 2022 |
Description of the Registrant’s Securities Exhibit 4.5 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2021, Hoth Therapeutics, Inc. (?the Company?) had one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), its common stock, par value $0.0001 per share (the ?Common Stock?). Description |
|
| February 23, 2022 |
HOTH / Hoth Therapeutics Inc / Iroquois Capital Management, LLC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44148G105 (CUSIP Number) December 31, 2021 (Date o |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 9, 2022 |
HOTH / Hoth Therapeutics Inc / Lind Global Macro Fund LP Passive Investment SC 13G/A 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 44148G105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 4, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) HOTH THERAPEUTICS, INC. |
|
| February 4, 2022 |
As filed with the Securities and Exchange Commission on February 4, 2022 As filed with the Securities and Exchange Commission on February 4, 2022 ?Registration No. |
|
| February 4, 2022 |
Exhibit 10.1 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN EFFECTIVE AS OF MAY 4, 2018 HOTH THERAPEUTICS, INC. 2018 EQUITY INCENTIVE PLAN EFFECTIVE AS OF MAY 4, 2018 SECTION 1. INTRODUCTION. The Company?s Board of Directors adopted the Hoth Therapeutics, Inc. 2018 Equity Incentive Plan effective as of the Adoption Date subject to obtaining Company shareholder approval as provided in Section 1 |
|
| February 3, 2022 |
HOTH / Hoth Therapeutics Inc / Ionic Ventures, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 44148G 10 5 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 19, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| January 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2022 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 30, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| January 4, 2022 |
EX-99.1 2 ea153383ex99-1hoththerap.htm PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED JANUARY 4, 2022 Exhibit 99.1 Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Positive Results - Reduce Amyloid β in Alzheimer’s Disease Significant decrease in Aβ seen in an Alzheimer’s disease mouse model after acute treatment with HT-ALZ, supporting that HT-ALZ has the potential to modify Aβ plaque formati |
|
| December 8, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission F |
|
| December 8, 2021 |
Exhibit 99.1 Hoth Therapeutics Licenses Lupus Therapeutic Back to Zyl? Therapeutics Hoth to receive shares in Zyl? and potential future sales royalties NEW YORK, NY December 8, 2021 /PR Newswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into a |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| September 1, 2021 |
EX-99.1 2 ea146814ex99-1hoththera.htm PRESENTATION MATERIALS Exhibit 99.1 Clinical - Stage Biopharmaceutical Company Focused on Next Generation Therapeutics Meeting Unmet Patient Needs SEPTEMBER 2021 Safe Harbor Sta t ement This presentation contains "forward - looking statements" within the meaning of the “safe - harbor” provisions of the Private Securities Litigation Reform Act of 1995 . These s |
|
| September 1, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 1, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission |
|
| August 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| June 30, 2021 |
Exhibit 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (this ?Amendment?) to the Employment Agreement is dated as of June 25, 2021, and effective as of July 1, 2021, and is entered into by and between Hoth Therapeutics, Inc., a Nevada corporation (the ?Corporation?), and Stefanie Johns (the ?Employee?). All capitalized terms used herein but not otherwise defined shall have the |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 24, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| June 30, 2021 |
Exhibit 10.1 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment (this ?Amendment?) to the Amended and Restated Employment Agreement dated as of June 25, 2021, and effective as of July 1, 2021, is entered into between by and between Hoth Therapeutics, a Nevada corporation (the ?Corporation?), and Robb Knie (the ?Executive?). All capitalized terms used herein but not o |
|
| June 30, 2021 |
Exhibit 10.3 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amendment (this ?Amendment?) to the Employment Agreement dated as of June 25, 2021, and effective as of July 1, 2021, is entered into between by and between Hoth Therapeutics, a Nevada corporation (the ?Company?), and Jane H. Springer (the ?Employee?). All capitalized terms used herein but not otherwise defined sh |
|
| June 30, 2021 |
Exhibit 99.1 Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis The primary objectives were achieved in cohort one BioLexa was well-tolerated with no treatment related adverse events Initiating Cohort 2 patient screening in September NEW YORK, NY June 28, 2021/ PR Newswire/ Today, Hoth Therapeutics, I |
|
| June 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 17, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 24, 2021 |
Exhibit 99.1 Introduction to HT - KIT an mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell - Derived Cancers Safe Harbor Statement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ?could,? ?believe |
|
| May 24, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 24, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File |
|
| May 24, 2021 |
Exhibit 99.2 m o c . s c NASDAQ: HOTH i t u e ap r e h t h t o h www. 1 Introduction to HT - 001 Topical Gel www.hoththerapeutics.com N A S D A Q: HOTH 2 Safe Harbor Sta t ement This presentation contains "forward - looking statements" within the meaning of the ?safe - harbor? provisions of the Private Securities Litigation Reform Act of 1995 . These statements are identified by the use of words ? |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38803 Hoth Therapeutics, Inc. |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 3, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| May 7, 2021 |
- DEFINITIVE REVISED PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 12, 2021 Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 001-38803 82-1553794 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 6, 2021 |
15,569,621 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-254638 PROSPECTUS 15,569,621 Shares of Common Stock The selling shareholders named in this prospectus may use this prospectus to offer and resell from time to time up to 15,569,621 shares of our common stock, par value $0.0001 per share, which are comprised of (i) 6,826,962 shares (the “Shares”) of our common stock issued in a private placement |
|
| March 30, 2021 |
Hoth Therapeutics, Inc. 1 Rockefeller Plaza, Suite 1039 New York, New York 10020 March 30, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller Re: Hoth Therapeutics, Inc. Registration Statement on Form S-3 Filed March 23, 2021 File No. 333-254638 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regul |
|
| March 29, 2021 |
United States securities and exchange commission logo March 29, 2021 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. |
|
| March 29, 2021 |
United States securities and exchange commission logo March 29, 2021 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. |
|
| March 23, 2021 |
As filed with the U.S. Securities and Exchange Commission on March 23, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HOTH THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Nevada 82-1553794 (State or other jurisdiction of (I.R.S. Employer incorporation or or |
|
| March 18, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* Hoth Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 44148G105 (CUSIP Number) March 10, 2021 (Date of Ev |
